Fluidigm to Present at Upcoming Health Care Investor Conference
10 nov. 2020 08h30 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Vystar Contracts Partners for Production of Rx3000 UV Light Air Purifiers that Inactivate Airborne Viruses
06 août 2020 12h54 HE
|
Vystar Corp.
New manufacturer offers “Made in the USA” expanded production capacity, quality & fast deliveryRx3000® FDA certified Class II Medical device inactivates 99.97% of harmful airborne viruses &...
Study of BioAegis’ Lead Product, Gelsolin, is Key Component of NIAID Strategic Plan for COVID-19 Research
21 mai 2020 13h58 HE
|
BioAegis Therapeutics
MORRISTOWN, N.J., May 21, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc. announces that the National Institute of Health (NIH) Clinical Center is measuring patient gelsolin levels as part of...
Fluidigm and Next Gen Diagnostics Enter into Agreement to Improve the Efficiency of Pathogen Sample Preparation for Microbial Whole Genome Sequencing
03 mars 2020 08h00 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif. and HINXTON, United Kingdom, March 03, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an industry leader in microfluidics technology, and Next Gen...
Summit Therapeutics Reports Ridinilazole Significantly Improved Short and Longer-Term Quality of Life Measures in Patients with C. difficile Infection Compared to Standard of Care
03 oct. 2019 07h00 HE
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics Reports Ridinilazole Significantly Improved Short and Longer-Term Quality of Life Measures in Patients with C. difficile...
Summit Therapeutics to Host R&D Day 7 October 2019
25 sept. 2019 07h00 HE
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics to Host R&D Day 7 October 2019 Oxford, UK, and Cambridge, MA, US, 25 September 2019 – Summit Therapeutics plc...
Summit Therapeutics to Present Data from Phase 2 Clinical Trial of Ridinilazole at ID Week 2019
24 sept. 2019 07h00 HE
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics to Present Data from Phase 2 Clinical Trial of Ridinilazole at ID Week 2019 Oxford, UK, and Cambridge, MA, US,...
Vystar to Resume Production of Rx3000 UV Light Air Purifiers for Use in Hospitals, Healthcare Facilities
07 févr. 2019 09h18 HE
|
Vystar Corp
Destroys on first pass more than 99.97% of harmful airborne viruses and bacteria.Inactivates pathogens that cause measles, the common cold, MRSA (staph), whooping cough, TB, pneumonia and other...
Cidara Provides Corporate Update and Reports Second Quarter 2018 Financial Results
08 août 2018 16h30 HE
|
Cidara Therapeutics, Inc.
SAN DIEGO, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial...
How to Treat Minor Cuts; American Academy of Dermatology
10 juil. 2018 14h00 HE
|
American Academy of Dermatology
ROSEMONT, Ill., July 10, 2018 (GLOBE NEWSWIRE) -- Cuts from a sharp knife or a piece of glass are very common. They often occur while people are preparing food, washing dishes or even crafting. All...